Lipid abnormalities in Greek patients with coronary artery disease

International Journal of Cardiology

Volumn 59, Issue 2, 1997, Pages 177-184

  Elisaf, Moses S ^a   Siamopoulos, Kostas C ^a   Tselegarides, Theophilos J ^a   Bairaktari, Eleni Th ^a   Goudevenos, John A ^a   Tselepis, Alexandros D ^a   Tsolas, Orestes E ^a   Sideris, Dimitrios A ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

apolipoprotein B; coronary artery disease; lipid parameters; lipoprotein (a); lipoprotein phenotypes

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DYSLIPIDEMIA; FEMALE; GREECE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RISK FACTOR;

AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CASE-CONTROL STUDIES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY DISEASE; FEMALE; GREECE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; HYPERLIPOPROTEINEMIAS; HYPERTRIGLYCERIDEMIA; HYPOLIPOPROTEINEMIAS; LIPOPROTEIN(A); LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PHENOTYPE; RISK FACTORS; TRIGLYCERIDES;

EID: 0030997049     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(96)02916-6     Document Type: Article

References (33)

1. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). J Am Med Assoc 1986;256:2823-2828.
2. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361 662 men. Lancet 1986;II:933-936.
3. Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary heart disease. Am J Cardiol 1991;67:1185-1189.
4. Miller GJ, Miller NE. Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet 1975;I:16-18.
5. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994;121:641-647.
6. Kwiterovich PO, Coresh J, Bachorik PS. Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged ≤50 years) and women (≤60 years) with coronary artery disease. Am J Cardiol 1993;71:631-639.
7. Sniderman AD, Wolfson C, Teng B, Franklin FA, Bachorik PS, Kwiterovich PO Jr. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med 1982;97:833-839.
8. Genest J Jr, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, Wilson PWF, Salem DN, Schaefer EJ. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992;19:792-802.
9. Hearn JA, DeMario Jr SJ, Roubin GS, Hammanstrom M, Squoutas D. Predictive value of lipoprotein (a) and other serum lipoproteins in the angiographic diagnosis of coronary artery disease. Am J Cardiol 1990;66:1176-1180.
10. Pearson TA. Risk factors for arteriographically defined coronary artery disease (PhD dissertation). Baltimore: Johns Hopkins School of Hygiene and Public Health, Department of Epidemiology, 1983.
11. Pearson TA, Bulkley BH, Achuff SC, Kwiterovich PO, Gordis L. The association of low levels of HDL cholesterol and arteriographically defined coronary artery disease. Am J Epidemiol 1979;109:285-295.
12. Austen WG, Edward JE, Frye RC, Gensini GC, Gott VL, Griffith CCS, Goon DC, Murphy ML, Rowe BB. A reporting system on patients evaluated for coronary artery disease. Report of the Adhoc Committee for Grading of Coronary Artery Disease, Counsel on Cardiovascular Surgery, American Heart Association. Circulation 1975;51(suppl):5-40.
13. Silberman SR, Armentrout MA, Vella FA, Saha AL. MACRA (TM) Lp(a) for quantitation of human lipoprotein (a) by enzyme linked immunoassay (abstract). Clin Chem 1990;36:961.
14. LaRosa JC, Chambless LE, Criqui MH, Frantz ID, Glueck CJ, Heiss G, Morrison J. Patterns of dyslipoproteinemia in selected North American populations. The Lipid Research Clinics Program Prevalence Study. Circulation 1986;73 (suppl. I):112-129.
15. Beaumont JT, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T. Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull WHO 1970;43:891-915.
16. Bloomfield-Rubins H, Schectman G, Wilt TJ, Iwane MK. Distribution of lipid phenotypes in community-living men with coronary heart disease. Arch Intern Med 1992;152:2412-2416.
17. Kwiterovich PO Jr, White S, Forte T, Bachorik PS, Smith H, Sniderman AD. Hyperapobetalipoproteinemia in a kindred with familial combined hyperlipidemia and familial hypercholesterolemia. Arteriosclerosis 1987;7:211-225.
18. Dahlen GH, Guyton JR, Attar H, Farmer JA, Kantz TA, Gotto AM Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74:758-765.
19. Genest JJ, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PWF, Salem DN, Schaefer EJ. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-2033.
20. Lamarche B, Després J-P, Moorjiani S, Cantin B, Dagenais GR, Lupien P-J. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec cardiovascular study). Am J Cardiol 1995;75:1189-1195.
21. Kwiterovich PO Jr, Coresh J, Smith HH, Bachorik PS, Derby CA, Pearson TA. A comparison of the plasma levels of apolipoproteins B and A-1 and other risk factors in men and women with premature coronary artery disease. Am J Cardiol 1992;69:1015-1021.
22. Brown BG, Alberts JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-1298.
23. Stampfer MJ, Sacks FM, Salvini S, Willet WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373-381.
24. Wald NJ, Law M, Watt HC, Wu T, Bailey A, Johnson AM, Craig WY, Ledue TB, Haddow JE. Apolipoproteins and ischemic heart disease: implications for screening. Lancet 1994;343:75-79.
25. Grundy SM, Vega GL. Role of apolipoprotein levels in clinical practice. Arch Intern Med 1990;150:1579-1582.
26. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J 1990;301:1248-1251.
27. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, ChapelHill NC, Lippel K, Levy RI. Lipoprotein (a) levels and risk of coronary heart disease in men. J Am Med Assoc 1994;271:999-1003.
28. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein (a) and the risk of myocardial infarction. J Am Med Assoc 1993;270:2195-2199.
29. Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994;120:1012-1025.
30. Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions. The association between triglyceride and coronary heart disease. N Engl J Med 1980;302:1383-1389.
31. Brunzell JD, Schrott HG, Motulsky AG, Bierman EL. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 1976;25:313-320.
32. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506.
33. Craig WX, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. Br Med J 1989;298:784-788.